Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adg116
- Development stage
- Phase 1
- Lead developer
- Adagene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADG116 is a fully human anti-CTLA-4 monoclonal antibody developed using Adagene’s NEObody technology. It targets a unique and highly conserved epitope of CTLA-4, enabling species cross-reactivity for robust preclinical studies. ADG116 acts through partial CD80/86 ligand blockade and enhanced regulatory T-cell (Treg) depletion via strong antibody-dependent cellular cytotoxicity (ADCC), resulting in immune activation with potentially improved safety and efficacy compared to existing anti-CTLA-4 therapies like ipilimumab. The drug is being evaluated as monotherapy and in combination with pembrolizumab for advanced/metastatic solid tumors, currently in phase 1b/2 clinical development.
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD80 (T-lymphocyte activation antigen CD80)
Beyond the preview
Go deeper on adg116.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adg116.